Constantiam is accelerating the development of life-saving precision medicines by elucidating the consequences of human genetic variation, including developing novel allosteric modulators for unmet needs in the rare disease therapeutics space. Our RareScan platform enables the identification of patients who are more likely to benefit from precision therapies by uncovering the impact of genetic variants on disease and drug-responsiveness, thereby addressing a key element of drug development risk and capturing tens-to-hundreds of millions in additional revenue. Constantiam's key differentiator is our unique focus on massively-multiplexed experiments that measure the impact of thousands of genetic variants in a single experiment, and our integration of experimental data with probabilistic machine learning. We are also the developer of MAVEvidence, an innovative software platform for genetic testing companies and diagnostics labs that leverages related technologies to unlock conclusive diagnoses for patients and physicians.

Constantiam Biosciences

Org chart

Teams

Offices